🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Diyarbakır
Clinical trial register · Turkey

Clinical Trials in Diyarbakır, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Turkey and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5432 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5432
Studies in scope
all four open statuses
2496
Recruiting now
open to new participants
552
Lead sponsors
across recruiting studies
Top sites
Ankara 26 Adana 21 Antalya 20 Istanbul 20 Edirne 17
Narrow the registerReset
Recruitment status
Phase
Site location
Ankara26 Adana21 Antalya20 Istanbul20 Edirne17
All 38 locations
Target enrolment
to

Trials with a site in Diyarbakır

10 of 5432 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Turkey
Start
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Adana, Adapazarı, Ankara, Antalya, Diyarbakır, Edirne, Gaziantep, Istanbul
2025-12-12
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Adana, Ankara, Antalya, Bornova, Diyarbakır, Edirne, Gaziantep, Pendik
2025-11-28
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,264
Adana, Ankara, Antalya, Bursa, Diyarbakır, Istanbul, Izmir, Kocaeli
2023-12-21
Active, closed
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252Type 2 Diabetes, Obesity
Eli Lilly and Company
Phase 2
414
Kadıköy, Adana, Antalya, Bursa, Diyarbakır, Gaziantep, Istanbul, Samsun
2023-09-21
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Adana, Adapazarı, Altindağ, Ankara, Antalya, Bursa, Diyarbakır, Edirne
2022-10-04
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
Eli Lilly and Company
Phase 3
925
Stanbul, Izmir, Karsiyaka, Adana, Ankara, Diyarbakır, Edirne, Istanbul, Malatya
2022-04-14
Active, closed
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567Breast Neoplasm, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
368
Cordaleo, Meram, Adana, Ankara, Diyarbakır, Edirne, Istanbul, Malatya
2022-03-11
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
152
Bornova, Izmir, Karsiyaka, Adana, Ankara, Antalya, Bursa, Diyarbakır, Edirne
2021-12-20
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Stanbul, Üsküdar / Stanbul, Adana, Ankara, Antalya, Diyarbakır, Edirne, Istanbul
2021-10-04
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3
261
Bornova, Adana, Ankara, Antalya, Diyarbakır, Edirne, Istanbul, Izmir
2020-02-17
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Turkish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-turkey/city/diyarbak-r

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Turkey and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,432 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies with a site in Diyarbakır that also match the filters currently applied.

How many clinical trials are recruiting in Diyarbakır?

3 of the 10 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diyarbakır), 10 studies
PhaseStudiesRecruitingShare
Phase 38280%
Phase 22120%

Most active sponsors

Lead sponsors with the most studies (Diyarbakır)
Lead sponsorStudiesRecruiting
Eli Lilly and Company103
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.